The following attendance rates were estimated: 81% (range: 76% - 85%) for routine smear, 79% (range: 77% - 80%) for repeat smear (age <35); 85% (range: 84% - 87%) for repeat smear (age >/= 35), 95% (range: 97% - 93%) for colposcopy (age <35), and 93% (range: 90% - 96%) for colposcopy (age >/=35).
The prevalence of HPV infection at age 15 was 0.1, while the prevalence of CIN-1 at age 15 was 0.01.
The age-specific incidence of HPV infection was 0.051-0.089 for ages 15 to 19 years, 0.078-0.051 for ages 20 to 23 years, 0.025 for ages 24 to 29 years, 0.005 for ages 30 to 49 years, and 0.003 for ages >/= 50 years.
The age-specific regression rates of HPV infection were 0.33 (range: 0.26 - 0.54) for ages 15 to 24, 0.21 (range: 0.18 - 0.26) for ages 25 to 29, 0.05 (range: 0.03 - 0.07) for ages >/= 30.
The progression rate from HPV to CIN-1 was 0.04 (range: 0.03 - 0.06).
The proportion of HPV infections progressing to CIN-2 or CIN-3 was 0.1 (range: 0.05 - 0.5).
The regression rate from CIN-1 to HPV or healthy was 0.084 (range: 0.074 - 0.126) for ages 15 to 34 and 0.042 (range: 0.029 - 0.074) for ages >/= 35.
The proportion of CIN-1 reverting to healthy was 0.9 (range: 0.5 - 1.0).
The progression rate from CIN-1 to CIN-2 or CIN-3 was 0.0087 (range: 0.0087 - 0.029) for ages 15 to 34 and 0.035 (range: 0.029 - 0.056) for ages >/= 35.
The regression rate from CIN2/3 to CIN1 or healthy was 0.035 (range: 0.0292 - 0.056).
The proportion of CIN2/3 reverting to healthy was 0.5 (range: 0 -0.5).
The progression rate from CIN2/3 to invasive cancer was 0.025 (range: 0.018 - 0.034).
The sensitivity and specificity of HPV testing were, respectively, 0.948 (range: 0.927 - 0.969) and 0.673 (range: 0.582 - 0.764).
The effectiveness of colposcopy was 90% (range: 80% - 100%).
The progression rate from stage I to stage II was 0.13.
The probability of symptoms in stage I was 0.08.
The progression rate from stage II to stage III was 0.23.
The probability of symptoms in stage II was 0.12.
The progression rate from stage III to stage IV was 0.44.
The probability of symptoms in stage III was 0.37.
The probability of symptoms in stage IV was 0.68.
The annual probability of survival after invasive cancer diagnosis was 0.97-0.99 for stage I, 0.77-0.96 for stage II, 0.54-0.90 for stage III, and 0.49-0.88 for stage IV.